2.9802 0.09 (3.12%) | 04-17 14:46 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 4.07 | 1-year : | 4.91 |
Resists | First : | 3.48 | Second : | 4.21 |
Pivot price | 3.11 | |||
Supports | First : | 2.31 | Second : | 1.93 |
MAs | MA(5) : | 3.05 | MA(20) : | 3.22 |
MA(100) : | 2.13 | MA(250) : | 1.88 | |
MACD | MACD : | 0 | Signal : | 0.1 |
%K %D | K(14,3) : | 24.7 | D(3) : | 29.7 |
RSI | RSI(14): 50 | |||
52-week | High : | 6.46 | Low : | 1.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LVTX ] has closed above bottom band by 37.4%. Bollinger Bands are 40.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 41 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 3.05 - 3.06 | 3.06 - 3.08 |
Low: | 2.84 - 2.86 | 2.86 - 2.88 |
Close: | 2.86 - 2.89 | 2.89 - 2.92 |
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Thu, 21 Mar 2024
LAVA Therapeutics Announces Progress and Stability - TipRanks.com - TipRanks
Wed, 20 Mar 2024
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results - GlobeNewswire
Wed, 20 Mar 2024
Jefferies maintains Buy on Lava Therapeutics, stock target at $6 - Investing.com
Tue, 05 Mar 2024
Lava stock slips despite $7M from Pfizer (NASDAQ:LVTX) - Seeking Alpha
Fri, 01 Mar 2024
Premarket Mover: LAVA Therapeutics NV (LVTX) Down 12.91% - InvestorsObserver
Fri, 01 Mar 2024
LAVA Therapeutics (NASDAQ:LVTX) Has Debt But No Earnings; Should You Worry? - Simply Wall St
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 26 (M) |
Held by Insiders | 1.207e+007 (%) |
Held by Institutions | 28.7 (%) |
Shares Short | 56 (K) |
Shares Short P.Month | 0 (K) |
EPS | -4.264e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -1 % |
Return on Assets (ttm) | 541.6 % |
Return on Equity (ttm) | -22.1 % |
Qtrly Rev. Growth | 6.77e+006 % |
Gross Profit (p.s.) | -137.47 |
Sales Per Share | -97.12 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -1.6 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -39 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.04 |
Price to Cash Flow | 0.96 |
Dividend | 0 |
Forward Dividend | 211640 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |